{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.10.12","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"},"kaggle":{"accelerator":"nvidiaTeslaT4","dataSources":[{"sourceId":10526159,"sourceType":"datasetVersion","datasetId":6514663},{"sourceId":10548980,"sourceType":"datasetVersion","datasetId":6526982}],"dockerImageVersionId":30839,"isInternetEnabled":true,"language":"python","sourceType":"notebook","isGpuEnabled":true}},"nbformat_minor":4,"nbformat":4,"cells":[{"source":"<a href=\"https://www.kaggle.com/code/aditishere/nest-data?scriptVersionId=219332742\" target=\"_blank\"><img align=\"left\" alt=\"Kaggle\" title=\"Open in Kaggle\" src=\"https://kaggle.com/static/images/open-in-kaggle.svg\"></a>","metadata":{},"cell_type":"markdown"},{"cell_type":"code","source":"!pip install faiss-gpu\n!pip install faiss-cpu\nimport pandas as pd\n\nfile_path = '/kaggle/input/dataset/Problem Statements and Data Sets 2/usecase_1_.csv'\ndf = pd.read_csv(file_path)\ndf.head()","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:12:47.793726Z","iopub.execute_input":"2025-01-26T13:12:47.794017Z","iopub.status.idle":"2025-01-26T13:13:10.813894Z","shell.execute_reply.started":"2025-01-26T13:12:47.793986Z","shell.execute_reply":"2025-01-26T13:13:10.813094Z"}},"outputs":[{"name":"stdout","text":"Collecting faiss-gpu\n  Downloading faiss_gpu-1.7.2-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (1.4 kB)\nDownloading faiss_gpu-1.7.2-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (85.5 MB)\n\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m85.5/85.5 MB\u001b[0m \u001b[31m19.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m:00:01\u001b[0m00:01\u001b[0m\n\u001b[?25hInstalling collected packages: faiss-gpu\nSuccessfully installed faiss-gpu-1.7.2\nCollecting faiss-cpu\n  Downloading faiss_cpu-1.9.0.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (4.4 kB)\nRequirement already satisfied: numpy<3.0,>=1.25.0 in /usr/local/lib/python3.10/dist-packages (from faiss-cpu) (1.26.4)\nRequirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from faiss-cpu) (24.2)\nRequirement already satisfied: mkl_fft in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (1.3.8)\nRequirement already satisfied: mkl_random in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (1.2.4)\nRequirement already satisfied: mkl_umath in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (0.1.1)\nRequirement already satisfied: mkl in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (2025.0.1)\nRequirement already satisfied: tbb4py in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (2022.0.0)\nRequirement already satisfied: mkl-service in /usr/local/lib/python3.10/dist-packages (from numpy<3.0,>=1.25.0->faiss-cpu) (2.4.1)\nRequirement already satisfied: intel-openmp>=2024 in /usr/local/lib/python3.10/dist-packages (from mkl->numpy<3.0,>=1.25.0->faiss-cpu) (2024.2.0)\nRequirement already satisfied: tbb==2022.* in /usr/local/lib/python3.10/dist-packages (from mkl->numpy<3.0,>=1.25.0->faiss-cpu) (2022.0.0)\nRequirement already satisfied: tcmlib==1.* in /usr/local/lib/python3.10/dist-packages (from tbb==2022.*->mkl->numpy<3.0,>=1.25.0->faiss-cpu) (1.2.0)\nRequirement already satisfied: intel-cmplr-lib-rt in /usr/local/lib/python3.10/dist-packages (from mkl_umath->numpy<3.0,>=1.25.0->faiss-cpu) (2024.2.0)\nRequirement already satisfied: intel-cmplr-lib-ur==2024.2.0 in /usr/local/lib/python3.10/dist-packages (from intel-openmp>=2024->mkl->numpy<3.0,>=1.25.0->faiss-cpu) (2024.2.0)\nDownloading faiss_cpu-1.9.0.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (27.5 MB)\n\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m27.5/27.5 MB\u001b[0m \u001b[31m64.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m:00:01\u001b[0m00:01\u001b[0m\n\u001b[?25hInstalling collected packages: faiss-cpu\nSuccessfully installed faiss-cpu-1.9.0.post1\n","output_type":"stream"},{"execution_count":1,"output_type":"execute_result","data":{"text/plain":"   Unnamed: 0.1  Unnamed: 0   NCT Number  \\\n0             0           1  NCT03302091   \n1             1           2  NCT01948791   \n2             2           5  NCT04621591   \n3             3           6  NCT03130491   \n4             4           8  NCT01580891   \n\n                                         Study Title  \\\n0  A Study in People With Normal Kidney Function ...   \n1  16w Interventional Study on Titration and Dose...   \n2           Case Series With Saneso 360° Gastroscope   \n3  European Study Evaluating the EMBLOK Embolic P...   \n4  Evaluate the Clinical Equivalence of Two Nafti...   \n\n                                      Study URL   Acronym Study Status  \\\n0  https://clinicaltrials.gov/study/NCT03302091       NaN    COMPLETED   \n1  https://clinicaltrials.gov/study/NCT01948791  INSTINCT    COMPLETED   \n2  https://clinicaltrials.gov/study/NCT04621591       NaN    COMPLETED   \n3  https://clinicaltrials.gov/study/NCT03130491       NaN    COMPLETED   \n4  https://clinicaltrials.gov/study/NCT01580891       NaN    COMPLETED   \n\n                                       Brief Summary Study Results  \\\n0  The primary objective of the current study is ...           YES   \n1  To investigate the efficacy of Exelon capsule ...           YES   \n2  To confirm the procedural performance of the S...            NO   \n3  The primary objective is to evaluate the perfo...            NO   \n4  The objective of this study is to evaluate the...            NO   \n\n                    Conditions  ...  \\\n0  Renal Insufficiency|Healthy  ...   \n1          Alzheimer's Disease  ...   \n2                EGD Procedure  ...   \n3         Aortic Valve Disease  ...   \n4                  Tinea Pedis  ...   \n\n                                        Study Design  \\\n0  Allocation: NON_RANDOMIZED|Intervention Model:...   \n1  Allocation: NA|Intervention Model: SINGLE_GROU...   \n2  Allocation: NA|Intervention Model: SINGLE_GROU...   \n3  Allocation: NA|Intervention Model: SINGLE_GROU...   \n4  Allocation: RANDOMIZED|Intervention Model: PAR...   \n\n                  Other IDs  Start Date Primary Completion Date  \\\n0  1386-0002|2017-002180-18  2017-10-17              2018-08-16   \n1              CENA713BCN05     2014-08                 2015-09   \n2               SAN360UGICL  2020-08-01              2020-08-30   \n3               CLP002-2016  2017-03-08              2021-11-01   \n4               NTFC 1105.0     2012-05                 2013-03   \n\n  Completion Date First Posted Results First Posted Last Update Posted  \\\n0      2018-08-16   2017-10-04           2021-06-04         2021-06-04   \n1         2015-09   2013-09-24           2017-02-13         2017-02-13   \n2      2020-09-09   2020-11-09                  NaN         2020-11-10   \n3      2022-01-28   2017-04-26                  NaN         2024-03-05   \n4         2013-07   2012-04-19                  NaN         2014-05-06   \n\n                                           Locations  \\\n0  CRS Clinical Research Services Kiel GmbH, Kiel...   \n1  Novartis Investigative Site, Beijing, 100053, ...   \n2  Valley Endoscopy Center, Saint Clairsville, Oh...   \n3  Hospital San Donato, Milan, Milano, 20097, Ita...   \n4                                                NaN   \n\n                                     Study Documents  \n0  Study Protocol, https://cdn.clinicaltrials.gov...  \n1                                                NaN  \n2                                                NaN  \n3                                                NaN  \n4                                                NaN  \n\n[5 rows x 32 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Unnamed: 0.1</th>\n      <th>Unnamed: 0</th>\n      <th>NCT Number</th>\n      <th>Study Title</th>\n      <th>Study URL</th>\n      <th>Acronym</th>\n      <th>Study Status</th>\n      <th>Brief Summary</th>\n      <th>Study Results</th>\n      <th>Conditions</th>\n      <th>...</th>\n      <th>Study Design</th>\n      <th>Other IDs</th>\n      <th>Start Date</th>\n      <th>Primary Completion Date</th>\n      <th>Completion Date</th>\n      <th>First Posted</th>\n      <th>Results First Posted</th>\n      <th>Last Update Posted</th>\n      <th>Locations</th>\n      <th>Study Documents</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>1</td>\n      <td>NCT03302091</td>\n      <td>A Study in People With Normal Kidney Function ...</td>\n      <td>https://clinicaltrials.gov/study/NCT03302091</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The primary objective of the current study is ...</td>\n      <td>YES</td>\n      <td>Renal Insufficiency|Healthy</td>\n      <td>...</td>\n      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n      <td>1386-0002|2017-002180-18</td>\n      <td>2017-10-17</td>\n      <td>2018-08-16</td>\n      <td>2018-08-16</td>\n      <td>2017-10-04</td>\n      <td>2021-06-04</td>\n      <td>2021-06-04</td>\n      <td>CRS Clinical Research Services Kiel GmbH, Kiel...</td>\n      <td>Study Protocol, https://cdn.clinicaltrials.gov...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>1</td>\n      <td>2</td>\n      <td>NCT01948791</td>\n      <td>16w Interventional Study on Titration and Dose...</td>\n      <td>https://clinicaltrials.gov/study/NCT01948791</td>\n      <td>INSTINCT</td>\n      <td>COMPLETED</td>\n      <td>To investigate the efficacy of Exelon capsule ...</td>\n      <td>YES</td>\n      <td>Alzheimer's Disease</td>\n      <td>...</td>\n      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n      <td>CENA713BCN05</td>\n      <td>2014-08</td>\n      <td>2015-09</td>\n      <td>2015-09</td>\n      <td>2013-09-24</td>\n      <td>2017-02-13</td>\n      <td>2017-02-13</td>\n      <td>Novartis Investigative Site, Beijing, 100053, ...</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>2</td>\n      <td>5</td>\n      <td>NCT04621591</td>\n      <td>Case Series With Saneso 360° Gastroscope</td>\n      <td>https://clinicaltrials.gov/study/NCT04621591</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>To confirm the procedural performance of the S...</td>\n      <td>NO</td>\n      <td>EGD Procedure</td>\n      <td>...</td>\n      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n      <td>SAN360UGICL</td>\n      <td>2020-08-01</td>\n      <td>2020-08-30</td>\n      <td>2020-09-09</td>\n      <td>2020-11-09</td>\n      <td>NaN</td>\n      <td>2020-11-10</td>\n      <td>Valley Endoscopy Center, Saint Clairsville, Oh...</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>3</td>\n      <td>6</td>\n      <td>NCT03130491</td>\n      <td>European Study Evaluating the EMBLOK Embolic P...</td>\n      <td>https://clinicaltrials.gov/study/NCT03130491</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The primary objective is to evaluate the perfo...</td>\n      <td>NO</td>\n      <td>Aortic Valve Disease</td>\n      <td>...</td>\n      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n      <td>CLP002-2016</td>\n      <td>2017-03-08</td>\n      <td>2021-11-01</td>\n      <td>2022-01-28</td>\n      <td>2017-04-26</td>\n      <td>NaN</td>\n      <td>2024-03-05</td>\n      <td>Hospital San Donato, Milan, Milano, 20097, Ita...</td>\n      <td>NaN</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>4</td>\n      <td>8</td>\n      <td>NCT01580891</td>\n      <td>Evaluate the Clinical Equivalence of Two Nafti...</td>\n      <td>https://clinicaltrials.gov/study/NCT01580891</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The objective of this study is to evaluate the...</td>\n      <td>NO</td>\n      <td>Tinea Pedis</td>\n      <td>...</td>\n      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n      <td>NTFC 1105.0</td>\n      <td>2012-05</td>\n      <td>2013-03</td>\n      <td>2013-07</td>\n      <td>2012-04-19</td>\n      <td>NaN</td>\n      <td>2014-05-06</td>\n      <td>NaN</td>\n      <td>NaN</td>\n    </tr>\n  </tbody>\n</table>\n<p>5 rows × 32 columns</p>\n</div>"},"metadata":{}}],"execution_count":1},{"cell_type":"code","source":"print(df.columns)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:10.814674Z","iopub.execute_input":"2025-01-26T13:13:10.814919Z","iopub.status.idle":"2025-01-26T13:13:10.819534Z","shell.execute_reply.started":"2025-01-26T13:13:10.8149Z","shell.execute_reply":"2025-01-26T13:13:10.818602Z"}},"outputs":[{"name":"stdout","text":"Index(['Unnamed: 0.1', 'Unnamed: 0', 'NCT Number', 'Study Title', 'Study URL',\n       'Acronym', 'Study Status', 'Brief Summary', 'Study Results',\n       'Conditions', 'Interventions', 'Primary Outcome Measures',\n       'Secondary Outcome Measures', 'Other Outcome Measures', 'Sponsor',\n       'Collaborators', 'Sex', 'Age', 'Phases', 'Enrollment', 'Funder Type',\n       'Study Type', 'Study Design', 'Other IDs', 'Start Date',\n       'Primary Completion Date', 'Completion Date', 'First Posted',\n       'Results First Posted', 'Last Update Posted', 'Locations',\n       'Study Documents'],\n      dtype='object')\n","output_type":"stream"}],"execution_count":2},{"cell_type":"code","source":"criteria_file_path = '/kaggle/input/dataset/Problem Statements and Data Sets 2/eligibilities.txt'\nwith open(criteria_file_path, 'r') as f:\n    criteria_data = f.read().splitlines()\n\ncriteria_data[:5]\n# df_new['Criteria'] = criteria_data","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:10.820423Z","iopub.execute_input":"2025-01-26T13:13:10.820646Z","iopub.status.idle":"2025-01-26T13:13:20.628986Z","shell.execute_reply.started":"2025-01-26T13:13:10.820626Z","shell.execute_reply":"2025-01-26T13:13:20.6282Z"}},"outputs":[{"execution_count":3,"output_type":"execute_result","data":{"text/plain":"['id|nct_id|sampling_method|gender|minimum_age|maximum_age|healthy_volunteers|population|criteria|gender_description|gender_based|adult|child|older_adult',\n '6260055|NCT05050916||FEMALE|19 Years|40 Years|f||\"* INCLUSION CRITERIA:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Having natural, spontaneous menstrual cycles (no hormonal therapy) less than 50 days in length.~* Aged 19-40 years~* Ability to take a vitamin D capsule and willing to adhere to the weekly regimen~* If sexually active, use of a non-hormonal contraceptive method.~EXCLUSION CRITERIA:~An individual who meets any of the following criteria will be excluded from participation in this study:~* No menstrual period in the last 50 days, or, a typical menstrual cycle length \\\\<16 or \\\\>49 days.~* Use of a vitamin D supplement for more than one month and on more than 15 days out of each month. Volunteers will be asked to check their supplement label for vitamin D content.~* Unwilling to abstain from taking non-study vitamin D supplements during the study or if already taking a medically-advised vitamin D supplement.~* Use of a calcium supplement (including certain antacids) and unwilling to abstain from taking a calcium supplement during the study.~* Known polycystic ovarian syndrome~* Depo-provera use in the previous 12 months~* Current use of any hormones, including birth control~* Current use of a hormonal intrauterine device (IUD)~* Current pregnancy or lactation, trying to become pregnant, or planning to try in the next four menstrual cycles or 5 months.~* History of seizure disorders~* Celiac disease~* Crohn s Disease~* Body mass index \\\\>35~* Aged \\\\<19 or \\\\> 40 years~* Presence of known contraindications for vitamin D supplementation, history of any of the following: calcium disorder or hypercalcemia, tuberculosis or granulomatous disease, metastatic bone disease, sarcoidosis, Williams syndrome, kidney disease (kidney stones, renal failure or dialysis, lupus nephritis)~* Known liver disease (cirrhosis)~* History of cancer other than skin cancer.~* History of anorexia nervosa, bulimia or an eating disorder~* Use within the past 60 days, of exogenous hormones~* Type 1 or Type 2 diabetes~* Known heart disease~* Gastric bypass surgery~* Unwilling or unable to complete study activities, e.g. collect daily urine specimens, have blood drawn, complete daily diaries, attend in person study visits~  25. Non-English speaking~* Due to the complexity of daily/weekly diaries, testing and procedurerequirements, all consents, instructions and questionnaires are provided in English. Therefore, all participants must be able to able to read and speak English.\"|||t|f|f',\n '6260056|NCT01092156||FEMALE|18 Years||t||\"Inclusion Criteria:~* Pregnant women who intend to breastfeed their infants~* Single infant~* Resides in catchment area~* Has phone~* Speaks English\"|||t|f|t',\n '6260057|NCT01218256||ALL|30 Years|80 Years|f||\"Inclusion Criteria:~* type 2 diabetes mellitus~Exclusion Criteria:~* myocardial infarction within the last 6 months~* unstable angina pectoris~* left ventricular ejection fraction less than 40%~* orthopedic limitations that eliminate to perform resistance training\"|||t|f|t',\n '6260058|NCT03240432||ALL|60 Years||t||\"Inclusion Criteria:~To be eligible for the study, all participants must meet the following criteria:~1. Clinical diagnosis of insulin dependent presumed autoimmune type 1 diabetes by the investigator and meeting at least one of the following criteria:~   i. Age \\\\> 6 months and \\\\< 10 years old at diagnosis OR ii. Positive pancreatic autoantibodies at any time (GAD-65, IA-2, ICA or ZnT8) or positive anti-insulin autoantibody at diagnosis only (within 10 days of starting insulin) OR iii. Presence of 2 or more of the following clinical indicators suggestive of type 1 diabetes:~  1. Age at diagnosis \\\\< 40 years~  2. Non-obese at diagnosis according to BMI (\\\\< 95th percentile pediatric and \\\\< 30 kg/m2 adult)~  3. Diabetic ketoacidosis (DKA) at any time,~  4. Plasma C-peptide level \\\\< 0.8 ng/ml (with blood glucose \\\\> 80 mg/dL if available) at any time~  5. Family history of type 1 diabetes in a first degree relative (parent, sibling, or child).~2. Age ≥60 years~3. HbA1c \\\\<10.0% at screening or within 30 days prior to screening visit (the upper limit was selected as a surrogate measure of likelihood of adherence to the protocol with the belief that those with higher HbA1c levels are generally noncompliant with diabetes management and thus not good candidates for the trial)~4. Insulin regimen involves either use of an insulin pump (a minimum of 40% of study population) or multiple daily injections of insulin (minimum of 40% of study population).~5. Participant is able to manage his/her diabetes with respect to insulin administration and glucose monitoring (which may include assistance from spouse or other caregiver)~6. Participant understands the study protocol and agrees to comply with it~7. Participant comprehends written and spoken English~8. At least 240 hours (10 out of 14 days) of sensor glucose data with appropriate number of calibrations from the blinded CGM pre-randomization phase~Exclusion Criteria:~Individuals meeting any of the following exclusion criteria at baseline will be excluded from study participation.~1. Use of unblinded CGM, outside of a research study, as part of real-time diabetes management in the last 3 months~2. At least 10% of time spent with sensor glucose levels \\\\< 54 mg/dl during the blinded CGM screening period AND a severe hypoglycemic event in the past 6 months (a severe hypoglycemic event that required assistance of another person due to altered consciousness, and required another person to actively administer carbohydrate, glucagon, or other resuscitative actions (see section 8.1).~3. Extreme visual or hearing impairment that would impair ability to use real-time CGM assessed at screening visit~4. Known adhesive allergy or skin reaction during the blinded CGM pre-randomization phase that would preclude participation in the randomized trial~5. Plans to begin non-insulin medication for blood glucose lowering during the course of the study~6. Stage 4 or 5 renal disease or most recent GFR \\\\< 30 ml/min/m2 from local lab within the past 6 months~7. The presence of a significant medical or psychiatric condition or use of a medication that in the judgment of the investigator may affect completion of any aspect of the protocol, or is likely to be associated with life expectancy of \\\\<1 year.~8. Clinical diagnosis of dementia (cognitive impairment that is mild and not considered sufficient for diagnosis of dementia is acceptable)~9. Need for use of acetaminophen or acetaminophen-containing products on a regular basis during the 6 months of the trial (unless stipulation no longer required with use of newer generation sensors)~10. Inpatient psychiatric treatment in the past 6 months~11. Participation in an intervention study (including psychological studies) in past 6 weeks.~12. Expectation that participant will be moving out of the area of the clinical center during the next 6 months, unless the move will be to an area served by another study center.\"|||t|f|t']"},"metadata":{}}],"execution_count":3},{"cell_type":"code","source":"parsed_data = [line.split(\"|\") for line in criteria_data[1:]]\neligibility_dict = {line[1]: line[8] for line in parsed_data}","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:20.629796Z","iopub.execute_input":"2025-01-26T13:13:20.630053Z","iopub.status.idle":"2025-01-26T13:13:23.712976Z","shell.execute_reply.started":"2025-01-26T13:13:20.630031Z","shell.execute_reply":"2025-01-26T13:13:23.712322Z"}},"outputs":[],"execution_count":4},{"cell_type":"code","source":"df[\"eligibility\"] = df[\"NCT Number\"].map(eligibility_dict)\ndf","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:23.713741Z","iopub.execute_input":"2025-01-26T13:13:23.713961Z","iopub.status.idle":"2025-01-26T13:13:24.342616Z","shell.execute_reply.started":"2025-01-26T13:13:23.713943Z","shell.execute_reply":"2025-01-26T13:13:24.341739Z"}},"outputs":[{"execution_count":5,"output_type":"execute_result","data":{"text/plain":"        Unnamed: 0.1  Unnamed: 0   NCT Number  \\\n0                  0           1  NCT03302091   \n1                  1           2  NCT01948791   \n2                  2           5  NCT04621591   \n3                  3           6  NCT03130491   \n4                  4           8  NCT01580891   \n...              ...         ...          ...   \n117975        117975      150114  NCT00706654   \n117976        117976      150117  NCT05098054   \n117977        117977      150119  NCT06352554   \n117978        117978      150120  NCT00710554   \n117979        117979      150121  NCT03353454   \n\n                                              Study Title  \\\n0       A Study in People With Normal Kidney Function ...   \n1       16w Interventional Study on Titration and Dose...   \n2                Case Series With Saneso 360° Gastroscope   \n3       European Study Evaluating the EMBLOK Embolic P...   \n4       Evaluate the Clinical Equivalence of Two Nafti...   \n...                                                   ...   \n117975  Intramuscular Depot Formulation of Aripiprazol...   \n117976  A Study of Soticlestat in Adults With Liver Fa...   \n117977  Susceptibility Testing In Neisseria Gonorrhoea...   \n117978  A Study of Sativex® for Pain Relief of Periphe...   \n117979  A Placebo-controlled Study of Maralixibat (SHP...   \n\n                                           Study URL   Acronym  \\\n0       https://clinicaltrials.gov/study/NCT03302091       NaN   \n1       https://clinicaltrials.gov/study/NCT01948791  INSTINCT   \n2       https://clinicaltrials.gov/study/NCT04621591       NaN   \n3       https://clinicaltrials.gov/study/NCT03130491       NaN   \n4       https://clinicaltrials.gov/study/NCT01580891       NaN   \n...                                              ...       ...   \n117975  https://clinicaltrials.gov/study/NCT00706654    ASPIRE   \n117976  https://clinicaltrials.gov/study/NCT05098054       NaN   \n117977  https://clinicaltrials.gov/study/NCT06352554     STING   \n117978  https://clinicaltrials.gov/study/NCT00710554       NaN   \n117979  https://clinicaltrials.gov/study/NCT03353454       NaN   \n\n              Study Status                                      Brief Summary  \\\n0                COMPLETED  The primary objective of the current study is ...   \n1                COMPLETED  To investigate the efficacy of Exelon capsule ...   \n2                COMPLETED  To confirm the procedural performance of the S...   \n3                COMPLETED  The primary objective is to evaluate the perfo...   \n4                COMPLETED  The objective of this study is to evaluate the...   \n...                    ...                                                ...   \n117975           COMPLETED  The purpose of the this trial is to evaluate t...   \n117976           COMPLETED  The main aim is to check the effect of a singl...   \n117977  NOT_YET_RECRUITING  This study aims to validate a novel antibiotic...   \n117978           COMPLETED  The purpose of this study is to evaluate the e...   \n117979           WITHDRAWN  The purpose of this study is to determine if t...   \n\n       Study Results                                         Conditions  ...  \\\n0                YES                        Renal Insufficiency|Healthy  ...   \n1                YES                                Alzheimer's Disease  ...   \n2                 NO                                      EGD Procedure  ...   \n3                 NO                               Aortic Valve Disease  ...   \n4                 NO                                        Tinea Pedis  ...   \n...              ...                                                ...  ...   \n117975           YES                                      Schizophrenia  ...   \n117976           YES              Hepatic Impairment|Healthy Volunteers  ...   \n117977            NO           Diagnosis|Gonorrhea|Resistance Bacterial  ...   \n117978           YES                         Pain|Peripheral Neuropathy  ...   \n117979            NO  Progressive Familial Intrahepatic Cholestasis ...  ...   \n\n                                               Other IDs  Start Date  \\\n0                               1386-0002|2017-002180-18  2017-10-17   \n1                                           CENA713BCN05     2014-08   \n2                                            SAN360UGICL  2020-08-01   \n3                                            CLP002-2016  2017-03-08   \n4                                            NTFC 1105.0     2012-05   \n...                                                  ...         ...   \n117975                                         31-07-247     2008-09   \n117976                       TAK-935-1010|2021-006373-29  2021-10-29   \n117977  2023/ETH02474:STING|224842/Z/21/Z|75A50122C00028  2024-04-08   \n117978                                          GWCL0405     2005-08   \n117979                         SHP625-306|2017-003138-99  2018-10-25   \n\n       Primary Completion Date Completion Date First Posted  \\\n0                   2018-08-16      2018-08-16   2017-10-04   \n1                      2015-09         2015-09   2013-09-24   \n2                   2020-08-30      2020-09-09   2020-11-09   \n3                   2021-11-01      2022-01-28   2017-04-26   \n4                      2013-03         2013-07   2012-04-19   \n...                        ...             ...          ...   \n117975                 2012-08         2012-08   2008-06-27   \n117976              2022-05-31      2022-06-07   2021-10-28   \n117977              2024-12-30      2025-01-30   2024-04-08   \n117978                 2006-10         2006-10   2008-07-04   \n117979              2020-06-15      2020-06-15   2017-11-27   \n\n       Results First Posted Last Update Posted  \\\n0                2021-06-04         2021-06-04   \n1                2017-02-13         2017-02-13   \n2                       NaN         2020-11-10   \n3                       NaN         2024-03-05   \n4                       NaN         2014-05-06   \n...                     ...                ...   \n117975           2013-08-14         2013-08-14   \n117976           2024-02-02         2024-02-02   \n117977                  NaN         2024-04-09   \n117978           2012-09-14         2023-05-03   \n117979                  NaN         2019-03-18   \n\n                                                Locations  \\\n0       CRS Clinical Research Services Kiel GmbH, Kiel...   \n1       Novartis Investigative Site, Beijing, 100053, ...   \n2       Valley Endoscopy Center, Saint Clairsville, Oh...   \n3       Hospital San Donato, Milan, Milano, 20097, Ita...   \n4                                                     NaN   \n...                                                   ...   \n117975  Cerritos, California, 90703, United States|Esc...   \n117976  Velocity, Edgewater, Florida, 32132, United St...   \n117977                                                NaN   \n117978  Pain Clinic Office, Gartnavel General Hospital...   \n117979                                                NaN   \n\n                                          Study Documents  \\\n0       Study Protocol, https://cdn.clinicaltrials.gov...   \n1                                                     NaN   \n2                                                     NaN   \n3                                                     NaN   \n4                                                     NaN   \n...                                                   ...   \n117975                                                NaN   \n117976  Study Protocol, https://cdn.clinicaltrials.gov...   \n117977                                                NaN   \n117978                                                NaN   \n117979                                                NaN   \n\n                                              eligibility  \n0       \"Inclusion Criteria:~* Despite of moderate ren...  \n1       \"Key Inclusion Criteria:~* Have a diagnosis of...  \n2       \"Inclusion Criteria:~* 18 -74 years of age~* W...  \n3       \"Inclusion Criteria: Subject is between 18 and...  \n4       \"Inclusion Criteria:~* Male or non-pregnant, n...  \n...                                                   ...  \n117975  \"Inclusion Criteria:~* Subjects who are able t...  \n117976  \"Inclusion Criteria A. For Participants with H...  \n117977  \"Inclusion Criteria:~* Confirmed/suspected NG ...  \n117978  \"Inclusion Criteria:~* Willing and able to giv...  \n117979  \"Key Inclusion Criteria:~* Informed consent an...  \n\n[117980 rows x 33 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Unnamed: 0.1</th>\n      <th>Unnamed: 0</th>\n      <th>NCT Number</th>\n      <th>Study Title</th>\n      <th>Study URL</th>\n      <th>Acronym</th>\n      <th>Study Status</th>\n      <th>Brief Summary</th>\n      <th>Study Results</th>\n      <th>Conditions</th>\n      <th>...</th>\n      <th>Other IDs</th>\n      <th>Start Date</th>\n      <th>Primary Completion Date</th>\n      <th>Completion Date</th>\n      <th>First Posted</th>\n      <th>Results First Posted</th>\n      <th>Last Update Posted</th>\n      <th>Locations</th>\n      <th>Study Documents</th>\n      <th>eligibility</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>0</td>\n      <td>1</td>\n      <td>NCT03302091</td>\n      <td>A Study in People With Normal Kidney Function ...</td>\n      <td>https://clinicaltrials.gov/study/NCT03302091</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The primary objective of the current study is ...</td>\n      <td>YES</td>\n      <td>Renal Insufficiency|Healthy</td>\n      <td>...</td>\n      <td>1386-0002|2017-002180-18</td>\n      <td>2017-10-17</td>\n      <td>2018-08-16</td>\n      <td>2018-08-16</td>\n      <td>2017-10-04</td>\n      <td>2021-06-04</td>\n      <td>2021-06-04</td>\n      <td>CRS Clinical Research Services Kiel GmbH, Kiel...</td>\n      <td>Study Protocol, https://cdn.clinicaltrials.gov...</td>\n      <td>\"Inclusion Criteria:~* Despite of moderate ren...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>1</td>\n      <td>2</td>\n      <td>NCT01948791</td>\n      <td>16w Interventional Study on Titration and Dose...</td>\n      <td>https://clinicaltrials.gov/study/NCT01948791</td>\n      <td>INSTINCT</td>\n      <td>COMPLETED</td>\n      <td>To investigate the efficacy of Exelon capsule ...</td>\n      <td>YES</td>\n      <td>Alzheimer's Disease</td>\n      <td>...</td>\n      <td>CENA713BCN05</td>\n      <td>2014-08</td>\n      <td>2015-09</td>\n      <td>2015-09</td>\n      <td>2013-09-24</td>\n      <td>2017-02-13</td>\n      <td>2017-02-13</td>\n      <td>Novartis Investigative Site, Beijing, 100053, ...</td>\n      <td>NaN</td>\n      <td>\"Key Inclusion Criteria:~* Have a diagnosis of...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>2</td>\n      <td>5</td>\n      <td>NCT04621591</td>\n      <td>Case Series With Saneso 360° Gastroscope</td>\n      <td>https://clinicaltrials.gov/study/NCT04621591</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>To confirm the procedural performance of the S...</td>\n      <td>NO</td>\n      <td>EGD Procedure</td>\n      <td>...</td>\n      <td>SAN360UGICL</td>\n      <td>2020-08-01</td>\n      <td>2020-08-30</td>\n      <td>2020-09-09</td>\n      <td>2020-11-09</td>\n      <td>NaN</td>\n      <td>2020-11-10</td>\n      <td>Valley Endoscopy Center, Saint Clairsville, Oh...</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* 18 -74 years of age~* W...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>3</td>\n      <td>6</td>\n      <td>NCT03130491</td>\n      <td>European Study Evaluating the EMBLOK Embolic P...</td>\n      <td>https://clinicaltrials.gov/study/NCT03130491</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The primary objective is to evaluate the perfo...</td>\n      <td>NO</td>\n      <td>Aortic Valve Disease</td>\n      <td>...</td>\n      <td>CLP002-2016</td>\n      <td>2017-03-08</td>\n      <td>2021-11-01</td>\n      <td>2022-01-28</td>\n      <td>2017-04-26</td>\n      <td>NaN</td>\n      <td>2024-03-05</td>\n      <td>Hospital San Donato, Milan, Milano, 20097, Ita...</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria: Subject is between 18 and...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>4</td>\n      <td>8</td>\n      <td>NCT01580891</td>\n      <td>Evaluate the Clinical Equivalence of Two Nafti...</td>\n      <td>https://clinicaltrials.gov/study/NCT01580891</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The objective of this study is to evaluate the...</td>\n      <td>NO</td>\n      <td>Tinea Pedis</td>\n      <td>...</td>\n      <td>NTFC 1105.0</td>\n      <td>2012-05</td>\n      <td>2013-03</td>\n      <td>2013-07</td>\n      <td>2012-04-19</td>\n      <td>NaN</td>\n      <td>2014-05-06</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* Male or non-pregnant, n...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>117975</th>\n      <td>117975</td>\n      <td>150114</td>\n      <td>NCT00706654</td>\n      <td>Intramuscular Depot Formulation of Aripiprazol...</td>\n      <td>https://clinicaltrials.gov/study/NCT00706654</td>\n      <td>ASPIRE</td>\n      <td>COMPLETED</td>\n      <td>The purpose of the this trial is to evaluate t...</td>\n      <td>YES</td>\n      <td>Schizophrenia</td>\n      <td>...</td>\n      <td>31-07-247</td>\n      <td>2008-09</td>\n      <td>2012-08</td>\n      <td>2012-08</td>\n      <td>2008-06-27</td>\n      <td>2013-08-14</td>\n      <td>2013-08-14</td>\n      <td>Cerritos, California, 90703, United States|Esc...</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* Subjects who are able t...</td>\n    </tr>\n    <tr>\n      <th>117976</th>\n      <td>117976</td>\n      <td>150117</td>\n      <td>NCT05098054</td>\n      <td>A Study of Soticlestat in Adults With Liver Fa...</td>\n      <td>https://clinicaltrials.gov/study/NCT05098054</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The main aim is to check the effect of a singl...</td>\n      <td>YES</td>\n      <td>Hepatic Impairment|Healthy Volunteers</td>\n      <td>...</td>\n      <td>TAK-935-1010|2021-006373-29</td>\n      <td>2021-10-29</td>\n      <td>2022-05-31</td>\n      <td>2022-06-07</td>\n      <td>2021-10-28</td>\n      <td>2024-02-02</td>\n      <td>2024-02-02</td>\n      <td>Velocity, Edgewater, Florida, 32132, United St...</td>\n      <td>Study Protocol, https://cdn.clinicaltrials.gov...</td>\n      <td>\"Inclusion Criteria A. For Participants with H...</td>\n    </tr>\n    <tr>\n      <th>117977</th>\n      <td>117977</td>\n      <td>150119</td>\n      <td>NCT06352554</td>\n      <td>Susceptibility Testing In Neisseria Gonorrhoea...</td>\n      <td>https://clinicaltrials.gov/study/NCT06352554</td>\n      <td>STING</td>\n      <td>NOT_YET_RECRUITING</td>\n      <td>This study aims to validate a novel antibiotic...</td>\n      <td>NO</td>\n      <td>Diagnosis|Gonorrhea|Resistance Bacterial</td>\n      <td>...</td>\n      <td>2023/ETH02474:STING|224842/Z/21/Z|75A50122C00028</td>\n      <td>2024-04-08</td>\n      <td>2024-12-30</td>\n      <td>2025-01-30</td>\n      <td>2024-04-08</td>\n      <td>NaN</td>\n      <td>2024-04-09</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* Confirmed/suspected NG ...</td>\n    </tr>\n    <tr>\n      <th>117978</th>\n      <td>117978</td>\n      <td>150120</td>\n      <td>NCT00710554</td>\n      <td>A Study of Sativex® for Pain Relief of Periphe...</td>\n      <td>https://clinicaltrials.gov/study/NCT00710554</td>\n      <td>NaN</td>\n      <td>COMPLETED</td>\n      <td>The purpose of this study is to evaluate the e...</td>\n      <td>YES</td>\n      <td>Pain|Peripheral Neuropathy</td>\n      <td>...</td>\n      <td>GWCL0405</td>\n      <td>2005-08</td>\n      <td>2006-10</td>\n      <td>2006-10</td>\n      <td>2008-07-04</td>\n      <td>2012-09-14</td>\n      <td>2023-05-03</td>\n      <td>Pain Clinic Office, Gartnavel General Hospital...</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* Willing and able to giv...</td>\n    </tr>\n    <tr>\n      <th>117979</th>\n      <td>117979</td>\n      <td>150121</td>\n      <td>NCT03353454</td>\n      <td>A Placebo-controlled Study of Maralixibat (SHP...</td>\n      <td>https://clinicaltrials.gov/study/NCT03353454</td>\n      <td>NaN</td>\n      <td>WITHDRAWN</td>\n      <td>The purpose of this study is to determine if t...</td>\n      <td>NO</td>\n      <td>Progressive Familial Intrahepatic Cholestasis ...</td>\n      <td>...</td>\n      <td>SHP625-306|2017-003138-99</td>\n      <td>2018-10-25</td>\n      <td>2020-06-15</td>\n      <td>2020-06-15</td>\n      <td>2017-11-27</td>\n      <td>NaN</td>\n      <td>2019-03-18</td>\n      <td>NaN</td>\n      <td>NaN</td>\n      <td>\"Key Inclusion Criteria:~* Informed consent an...</td>\n    </tr>\n  </tbody>\n</table>\n<p>117980 rows × 33 columns</p>\n</div>"},"metadata":{}}],"execution_count":5},{"cell_type":"code","source":"columns_to_remove = ['Unnamed: 0.1', 'Unnamed: 0', 'Study URL','Acronym', 'Study Status', 'Brief Summary', \n                     'Study Results', 'Conditions', 'Interventions','Other Outcome Measures', 'Sponsor', 'Collaborators', \n                     'Sex', 'Age', 'Phases', 'Enrollment', 'Funder Type', 'Study Type', 'Study Design', 'Other IDs', \n                     'Start Date', 'Primary Completion Date', 'Completion Date', 'First Posted', 'Results First Posted', \n                     'Last Update Posted', 'Locations', 'Study Documents']\ndf = df.drop(columns=columns_to_remove)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:24.346794Z","iopub.execute_input":"2025-01-26T13:13:24.347061Z","iopub.status.idle":"2025-01-26T13:13:24.365464Z","shell.execute_reply.started":"2025-01-26T13:13:24.34704Z","shell.execute_reply":"2025-01-26T13:13:24.36482Z"}},"outputs":[],"execution_count":6},{"cell_type":"code","source":"df.columns","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:24.366097Z","iopub.execute_input":"2025-01-26T13:13:24.366326Z","iopub.status.idle":"2025-01-26T13:13:24.370975Z","shell.execute_reply.started":"2025-01-26T13:13:24.366306Z","shell.execute_reply":"2025-01-26T13:13:24.370389Z"}},"outputs":[{"execution_count":7,"output_type":"execute_result","data":{"text/plain":"Index(['NCT Number', 'Study Title', 'Primary Outcome Measures',\n       'Secondary Outcome Measures', 'eligibility'],\n      dtype='object')"},"metadata":{}}],"execution_count":7},{"cell_type":"code","source":"df = df.dropna(subset=['Study Title', 'Primary Outcome Measures', 'eligibility'])","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:24.371666Z","iopub.execute_input":"2025-01-26T13:13:24.371876Z","iopub.status.idle":"2025-01-26T13:13:24.456717Z","shell.execute_reply.started":"2025-01-26T13:13:24.371858Z","shell.execute_reply":"2025-01-26T13:13:24.456014Z"}},"outputs":[],"execution_count":8},{"cell_type":"code","source":"df","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:24.457495Z","iopub.execute_input":"2025-01-26T13:13:24.457699Z","iopub.status.idle":"2025-01-26T13:13:24.467541Z","shell.execute_reply.started":"2025-01-26T13:13:24.457682Z","shell.execute_reply":"2025-01-26T13:13:24.466819Z"}},"outputs":[{"execution_count":9,"output_type":"execute_result","data":{"text/plain":"         NCT Number                                        Study Title  \\\n0       NCT03302091  A Study in People With Normal Kidney Function ...   \n1       NCT01948791  16w Interventional Study on Titration and Dose...   \n2       NCT04621591           Case Series With Saneso 360° Gastroscope   \n3       NCT03130491  European Study Evaluating the EMBLOK Embolic P...   \n4       NCT01580891  Evaluate the Clinical Equivalence of Two Nafti...   \n...             ...                                                ...   \n117975  NCT00706654  Intramuscular Depot Formulation of Aripiprazol...   \n117976  NCT05098054  A Study of Soticlestat in Adults With Liver Fa...   \n117977  NCT06352554  Susceptibility Testing In Neisseria Gonorrhoea...   \n117978  NCT00710554  A Study of Sativex® for Pain Relief of Periphe...   \n117979  NCT03353454  A Placebo-controlled Study of Maralixibat (SHP...   \n\n                                 Primary Outcome Measures  \\\n0       Area Under the Concentration-time Curve of BI ...   \n1       Mean Change From Baseline in the Alzheimer's D...   \n2       Successful EGD, Procedure success is assessed ...   \n3       Performance Endpoint, successful insertion, pl...   \n4       Therapeutic Cure, Patients with both mycologic...   \n...                                                   ...   \n117975  Percentage of Patients Meeting Exacerbation of...   \n117976  Cmax: Maximum Observed Plasma Concentration fo...   \n117977  To determine the feasibility of performing ant...   \n117978  Change From Baseline in Mean Peripheral Neurop...   \n117979  Treatment Response as Measured by the Observer...   \n\n                               Secondary Outcome Measures  \\\n0       Area Under the Concentration-time Curve of BI ...   \n1       Change From Baseline in the Alzheimer's Diseas...   \n2       Endoscopist qualitative rating of the Saneso 3...   \n3       Safety Endpoint (Rate of MACCE), Rate of MACCE...   \n4                                                     NaN   \n...                                                   ...   \n117975  Time to Exacerbation of Psychotic Symptoms/Imp...   \n117976  Number of Participants Reporting One or More T...   \n117977  To study the performance of the InSignia assay...   \n117978  Change From Baseline in Neuropathic Pain Scale...   \n117979  Treatment Response as Measured by the Observer...   \n\n                                              eligibility  \n0       \"Inclusion Criteria:~* Despite of moderate ren...  \n1       \"Key Inclusion Criteria:~* Have a diagnosis of...  \n2       \"Inclusion Criteria:~* 18 -74 years of age~* W...  \n3       \"Inclusion Criteria: Subject is between 18 and...  \n4       \"Inclusion Criteria:~* Male or non-pregnant, n...  \n...                                                   ...  \n117975  \"Inclusion Criteria:~* Subjects who are able t...  \n117976  \"Inclusion Criteria A. For Participants with H...  \n117977  \"Inclusion Criteria:~* Confirmed/suspected NG ...  \n117978  \"Inclusion Criteria:~* Willing and able to giv...  \n117979  \"Key Inclusion Criteria:~* Informed consent an...  \n\n[113101 rows x 5 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>NCT Number</th>\n      <th>Study Title</th>\n      <th>Primary Outcome Measures</th>\n      <th>Secondary Outcome Measures</th>\n      <th>eligibility</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>NCT03302091</td>\n      <td>A Study in People With Normal Kidney Function ...</td>\n      <td>Area Under the Concentration-time Curve of BI ...</td>\n      <td>Area Under the Concentration-time Curve of BI ...</td>\n      <td>\"Inclusion Criteria:~* Despite of moderate ren...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>NCT01948791</td>\n      <td>16w Interventional Study on Titration and Dose...</td>\n      <td>Mean Change From Baseline in the Alzheimer's D...</td>\n      <td>Change From Baseline in the Alzheimer's Diseas...</td>\n      <td>\"Key Inclusion Criteria:~* Have a diagnosis of...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>NCT04621591</td>\n      <td>Case Series With Saneso 360° Gastroscope</td>\n      <td>Successful EGD, Procedure success is assessed ...</td>\n      <td>Endoscopist qualitative rating of the Saneso 3...</td>\n      <td>\"Inclusion Criteria:~* 18 -74 years of age~* W...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>NCT03130491</td>\n      <td>European Study Evaluating the EMBLOK Embolic P...</td>\n      <td>Performance Endpoint, successful insertion, pl...</td>\n      <td>Safety Endpoint (Rate of MACCE), Rate of MACCE...</td>\n      <td>\"Inclusion Criteria: Subject is between 18 and...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>NCT01580891</td>\n      <td>Evaluate the Clinical Equivalence of Two Nafti...</td>\n      <td>Therapeutic Cure, Patients with both mycologic...</td>\n      <td>NaN</td>\n      <td>\"Inclusion Criteria:~* Male or non-pregnant, n...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>117975</th>\n      <td>NCT00706654</td>\n      <td>Intramuscular Depot Formulation of Aripiprazol...</td>\n      <td>Percentage of Patients Meeting Exacerbation of...</td>\n      <td>Time to Exacerbation of Psychotic Symptoms/Imp...</td>\n      <td>\"Inclusion Criteria:~* Subjects who are able t...</td>\n    </tr>\n    <tr>\n      <th>117976</th>\n      <td>NCT05098054</td>\n      <td>A Study of Soticlestat in Adults With Liver Fa...</td>\n      <td>Cmax: Maximum Observed Plasma Concentration fo...</td>\n      <td>Number of Participants Reporting One or More T...</td>\n      <td>\"Inclusion Criteria A. For Participants with H...</td>\n    </tr>\n    <tr>\n      <th>117977</th>\n      <td>NCT06352554</td>\n      <td>Susceptibility Testing In Neisseria Gonorrhoea...</td>\n      <td>To determine the feasibility of performing ant...</td>\n      <td>To study the performance of the InSignia assay...</td>\n      <td>\"Inclusion Criteria:~* Confirmed/suspected NG ...</td>\n    </tr>\n    <tr>\n      <th>117978</th>\n      <td>NCT00710554</td>\n      <td>A Study of Sativex® for Pain Relief of Periphe...</td>\n      <td>Change From Baseline in Mean Peripheral Neurop...</td>\n      <td>Change From Baseline in Neuropathic Pain Scale...</td>\n      <td>\"Inclusion Criteria:~* Willing and able to giv...</td>\n    </tr>\n    <tr>\n      <th>117979</th>\n      <td>NCT03353454</td>\n      <td>A Placebo-controlled Study of Maralixibat (SHP...</td>\n      <td>Treatment Response as Measured by the Observer...</td>\n      <td>Treatment Response as Measured by the Observer...</td>\n      <td>\"Key Inclusion Criteria:~* Informed consent an...</td>\n    </tr>\n  </tbody>\n</table>\n<p>113101 rows × 5 columns</p>\n</div>"},"metadata":{}}],"execution_count":9},{"cell_type":"code","source":"import pandas as pd\nimport torch\nfrom transformers import AutoTokenizer, AutoModel\nfrom tqdm import tqdm ","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:24.468366Z","iopub.execute_input":"2025-01-26T13:13:24.468622Z","iopub.status.idle":"2025-01-26T13:13:32.285405Z","shell.execute_reply.started":"2025-01-26T13:13:24.468602Z","shell.execute_reply":"2025-01-26T13:13:32.284737Z"}},"outputs":[],"execution_count":10},{"cell_type":"code","source":"device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\ntokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-v1.1\")\nmodel = AutoModel.from_pretrained(\"dmis-lab/biobert-v1.1\").to(device)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:32.286206Z","iopub.execute_input":"2025-01-26T13:13:32.286591Z","iopub.status.idle":"2025-01-26T13:13:48.998684Z","shell.execute_reply.started":"2025-01-26T13:13:32.286568Z","shell.execute_reply":"2025-01-26T13:13:48.997215Z"}},"outputs":[{"output_type":"display_data","data":{"text/plain":"tokenizer_config.json:   0%|          | 0.00/49.0 [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"da8dbbe907c148e59bd0a1cb6852c131"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"config.json:   0%|          | 0.00/462 [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"4f940b1a27d64a328c7b1439330d1019"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"vocab.txt:   0%|          | 0.00/213k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3689df0c19b74b8280a9eaaff1196915"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"de960cd078114f89b006968a57e42813"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"pytorch_model.bin:   0%|          | 0.00/433M [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"de6c53bc91214bcb8e8e5dd8594469ef"}},"metadata":{}}],"execution_count":11},{"cell_type":"code","source":"import pandas as pd\nfrom tqdm import tqdm\nimport torch\n\ndef compute_embeddings_batch(texts):\n    # Tokenize the batch\n    encoded_input = tokenizer(\n        texts, padding=True, truncation=True, max_length=128, return_tensors=\"pt\"\n    ).to(device)\n    \n    # Compute embeddings\n    with torch.no_grad():\n        model_output = model(**encoded_input)\n    \n    # Return mean of the last hidden state as sentence embeddings\n    embeddings = model_output.last_hidden_state.mean(dim=1).cpu().numpy()\n    return embeddings\n\n# Define columns for which embeddings need to be created\nembedding_columns = [\"Study Title\", \"Primary Outcome Measures\", \"Secondary Outcome Measures\", \"eligibility\"] \nretain_columns = [\"NCT Number\"]  # Replace with the column you want to retain as it is\nbatch_size = 32  # Adjust batch size based on memory\n\n# Initialize new DataFrame\nembedding_df = pd.DataFrame()\n\n# Compute embeddings for selected columns\nfor column in embedding_columns:\n    if column not in df.columns:\n        print(f\"Column {column} does not exist in the DataFrame.\")\n        continue\n\n    print(f\"Processing column: {column}\")\n    texts = df[column].fillna(\"\").tolist()  # Handle NaN values\n    column_embeddings = []\n    \n    for i in tqdm(range(0, len(texts), batch_size)):\n        batch_texts = texts[i:i + batch_size]\n        batch_embeddings = compute_embeddings_batch(batch_texts)\n        column_embeddings.extend(batch_embeddings)\n    \n    # Add embeddings as a new column to the DataFrame\n    embedding_df[f\"{column}_embeddings\"] = column_embeddings\n\n# Retain the specified column as it is\nfor column in retain_columns:\n    if column not in df.columns:\n        print(f\"Column {column} does not exist in the DataFrame.\")\n        continue\n    embedding_df[column] = df[column]\n\n# Save the final DataFrame to disk\nembedding_df.to_parquet(\"final_dataframe_with_embeddings.parquet\")\nprint(\"New DataFrame with embeddings and the retained column saved!\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T13:13:49.000415Z","iopub.execute_input":"2025-01-26T13:13:49.00202Z","iopub.status.idle":"2025-01-26T14:07:09.145244Z","shell.execute_reply.started":"2025-01-26T13:13:49.001983Z","shell.execute_reply":"2025-01-26T14:07:09.144331Z"}},"outputs":[{"name":"stdout","text":"Processing column: Study Title\n","output_type":"stream"},{"name":"stderr","text":"100%|██████████| 3535/3535 [08:29<00:00,  6.93it/s]\n","output_type":"stream"},{"name":"stdout","text":"Processing column: Primary Outcome Measures\n","output_type":"stream"},{"name":"stderr","text":"100%|██████████| 3535/3535 [14:40<00:00,  4.01it/s]\n","output_type":"stream"},{"name":"stdout","text":"Processing column: Secondary Outcome Measures\n","output_type":"stream"},{"name":"stderr","text":"100%|██████████| 3535/3535 [14:53<00:00,  3.96it/s]\n","output_type":"stream"},{"name":"stdout","text":"Processing column: eligibility\n","output_type":"stream"},{"name":"stderr","text":"100%|██████████| 3535/3535 [15:00<00:00,  3.92it/s]\n","output_type":"stream"},{"name":"stdout","text":"New DataFrame with embeddings and the retained column saved!\n","output_type":"stream"}],"execution_count":12},{"cell_type":"code","source":"embedding_df","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T14:07:09.146362Z","iopub.execute_input":"2025-01-26T14:07:09.146696Z","iopub.status.idle":"2025-01-26T14:07:09.186858Z","shell.execute_reply.started":"2025-01-26T14:07:09.146662Z","shell.execute_reply":"2025-01-26T14:07:09.18616Z"}},"outputs":[{"execution_count":13,"output_type":"execute_result","data":{"text/plain":"                                   Study Title_embeddings  \\\n0       [-0.065264046, -0.092744045, -0.22700635, 0.17...   \n1       [-0.0053087957, -0.061169587, -0.08494293, 0.1...   \n2       [-0.22539619, -0.08245689, -0.3285748, 0.21585...   \n3       [-0.13534802, -0.20745067, -0.10994539, 0.2188...   \n4       [-0.11337181, -0.41438612, 0.036117, 0.3372785...   \n...                                                   ...   \n113096  [-0.1807382, -0.08000226, 0.065313324, 0.20722...   \n113097  [-0.07270654, -0.122345306, 0.024599317, 0.243...   \n113098  [0.047925193, 0.044782896, -0.2267468, 0.17400...   \n113099  [-0.064414054, -0.20857231, 0.057979308, 0.268...   \n113100  [-0.03297626, -0.078259744, -0.030716999, 0.29...   \n\n                      Primary Outcome Measures_embeddings  \\\n0       [0.05297418, -0.24113894, 0.0008954331, 0.1503...   \n1       [0.11766142, 0.013265373, -0.11087042, 0.26961...   \n2       [-0.059805617, -0.101662174, -0.018482223, 0.1...   \n3       [0.028187705, -0.103455745, -0.086739525, 0.11...   \n4       [0.019699685, -0.06446257, 0.11373979, 0.19213...   \n...                                                   ...   \n113096  [0.011189978, 0.113739885, 0.10325801, -0.0152...   \n113097  [0.103260934, -0.211911, 0.1612402, 0.05691315...   \n113098  [0.2012643, 0.054376222, -0.047303993, 0.07088...   \n113099  [0.16945687, -0.33824772, 0.040958915, 0.14733...   \n113100  [0.07109324, -0.11585969, -0.042776927, 0.0534...   \n\n                    Secondary Outcome Measures_embeddings  \\\n0       [0.05606445, -0.2799284, 0.071237825, 0.180695...   \n1       [0.020012934, -0.08214941, -0.19556046, 0.1607...   \n2       [0.057834648, -0.14884987, -0.06832139, 0.2609...   \n3       [-0.025586503, 0.1292601, -0.074246675, 0.0213...   \n4       [0.24691302, -0.17939429, -0.12142427, 0.08054...   \n...                                                   ...   \n113096  [-0.001914599, -0.031723417, 0.037113667, -0.0...   \n113097  [0.25566822, -0.16646692, -0.15347317, -0.0345...   \n113098  [0.23182309, 0.020095825, -0.0009980015, 0.078...   \n113099  [0.08082056, -0.22409007, -0.04124582, 0.14769...   \n113100  [0.011735199, -0.18996319, -0.08771389, 0.0061...   \n\n                                   eligibility_embeddings   NCT Number  \n0       [-0.09281416, -0.17330389, 0.08660969, 0.00623...  NCT03302091  \n1       [-0.082426585, -0.18671341, 0.007904554, 0.090...  NCT01948791  \n2       [7.056305e-05, -0.02793643, -0.010959615, 0.15...  NCT04621591  \n3       [0.008869184, -0.14230067, 0.09451622, 0.10525...  NCT03130491  \n4       [-0.035337817, -0.2909071, 0.02144168, 0.08162...  NCT01580891  \n...                                                   ...          ...  \n113096  [0.015561412, -0.13939855, 0.2855791, -0.02046...  NCT02165345  \n113097  [0.097778246, -0.0010176096, -0.052690737, 0.1...  NCT00407745  \n113098  [-0.0035707634, -0.08287071, 0.033421993, -0.0...  NCT01649245  \n113099  [-0.006804131, -0.16514528, 0.044964887, 0.087...  NCT00401245  \n113100  [0.057532623, -0.17629945, 0.04680439, 0.22762...  NCT01524445  \n\n[113101 rows x 5 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Study Title_embeddings</th>\n      <th>Primary Outcome Measures_embeddings</th>\n      <th>Secondary Outcome Measures_embeddings</th>\n      <th>eligibility_embeddings</th>\n      <th>NCT Number</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>[-0.065264046, -0.092744045, -0.22700635, 0.17...</td>\n      <td>[0.05297418, -0.24113894, 0.0008954331, 0.1503...</td>\n      <td>[0.05606445, -0.2799284, 0.071237825, 0.180695...</td>\n      <td>[-0.09281416, -0.17330389, 0.08660969, 0.00623...</td>\n      <td>NCT03302091</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>[-0.0053087957, -0.061169587, -0.08494293, 0.1...</td>\n      <td>[0.11766142, 0.013265373, -0.11087042, 0.26961...</td>\n      <td>[0.020012934, -0.08214941, -0.19556046, 0.1607...</td>\n      <td>[-0.082426585, -0.18671341, 0.007904554, 0.090...</td>\n      <td>NCT01948791</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>[-0.22539619, -0.08245689, -0.3285748, 0.21585...</td>\n      <td>[-0.059805617, -0.101662174, -0.018482223, 0.1...</td>\n      <td>[0.057834648, -0.14884987, -0.06832139, 0.2609...</td>\n      <td>[7.056305e-05, -0.02793643, -0.010959615, 0.15...</td>\n      <td>NCT04621591</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>[-0.13534802, -0.20745067, -0.10994539, 0.2188...</td>\n      <td>[0.028187705, -0.103455745, -0.086739525, 0.11...</td>\n      <td>[-0.025586503, 0.1292601, -0.074246675, 0.0213...</td>\n      <td>[0.008869184, -0.14230067, 0.09451622, 0.10525...</td>\n      <td>NCT03130491</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>[-0.11337181, -0.41438612, 0.036117, 0.3372785...</td>\n      <td>[0.019699685, -0.06446257, 0.11373979, 0.19213...</td>\n      <td>[0.24691302, -0.17939429, -0.12142427, 0.08054...</td>\n      <td>[-0.035337817, -0.2909071, 0.02144168, 0.08162...</td>\n      <td>NCT01580891</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>113096</th>\n      <td>[-0.1807382, -0.08000226, 0.065313324, 0.20722...</td>\n      <td>[0.011189978, 0.113739885, 0.10325801, -0.0152...</td>\n      <td>[-0.001914599, -0.031723417, 0.037113667, -0.0...</td>\n      <td>[0.015561412, -0.13939855, 0.2855791, -0.02046...</td>\n      <td>NCT02165345</td>\n    </tr>\n    <tr>\n      <th>113097</th>\n      <td>[-0.07270654, -0.122345306, 0.024599317, 0.243...</td>\n      <td>[0.103260934, -0.211911, 0.1612402, 0.05691315...</td>\n      <td>[0.25566822, -0.16646692, -0.15347317, -0.0345...</td>\n      <td>[0.097778246, -0.0010176096, -0.052690737, 0.1...</td>\n      <td>NCT00407745</td>\n    </tr>\n    <tr>\n      <th>113098</th>\n      <td>[0.047925193, 0.044782896, -0.2267468, 0.17400...</td>\n      <td>[0.2012643, 0.054376222, -0.047303993, 0.07088...</td>\n      <td>[0.23182309, 0.020095825, -0.0009980015, 0.078...</td>\n      <td>[-0.0035707634, -0.08287071, 0.033421993, -0.0...</td>\n      <td>NCT01649245</td>\n    </tr>\n    <tr>\n      <th>113099</th>\n      <td>[-0.064414054, -0.20857231, 0.057979308, 0.268...</td>\n      <td>[0.16945687, -0.33824772, 0.040958915, 0.14733...</td>\n      <td>[0.08082056, -0.22409007, -0.04124582, 0.14769...</td>\n      <td>[-0.006804131, -0.16514528, 0.044964887, 0.087...</td>\n      <td>NCT00401245</td>\n    </tr>\n    <tr>\n      <th>113100</th>\n      <td>[-0.03297626, -0.078259744, -0.030716999, 0.29...</td>\n      <td>[0.07109324, -0.11585969, -0.042776927, 0.0534...</td>\n      <td>[0.011735199, -0.18996319, -0.08771389, 0.0061...</td>\n      <td>[0.057532623, -0.17629945, 0.04680439, 0.22762...</td>\n      <td>NCT01524445</td>\n    </tr>\n  </tbody>\n</table>\n<p>113101 rows × 5 columns</p>\n</div>"},"metadata":{}}],"execution_count":13},{"cell_type":"code","source":"embedding_df.columns","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T14:07:09.187795Z","iopub.execute_input":"2025-01-26T14:07:09.188094Z","iopub.status.idle":"2025-01-26T14:07:09.198969Z","shell.execute_reply.started":"2025-01-26T14:07:09.188064Z","shell.execute_reply":"2025-01-26T14:07:09.198288Z"}},"outputs":[{"execution_count":14,"output_type":"execute_result","data":{"text/plain":"Index(['Study Title_embeddings', 'Primary Outcome Measures_embeddings',\n       'Secondary Outcome Measures_embeddings', 'eligibility_embeddings',\n       'NCT Number'],\n      dtype='object')"},"metadata":{}}],"execution_count":14},{"cell_type":"code","source":"import faiss\nimport numpy as np\n\n# Step 1: Combine embeddings into a single representation\nembedding_columns = [col for col in embedding_df.columns if col.endswith(\"_embeddings\")]\nprint(\"Embedding columns:\", embedding_columns)\n\n# Combine embeddings into a single NumPy array\nembeddings = np.hstack([np.vstack(embedding_df[col].to_numpy()) for col in embedding_columns])\nprint(f\"Combined embeddings shape: {embeddings.shape}\")\n\n# Step 2: Build and save the FAISS index\ndimension = embeddings.shape[1]  # Number of features per embedding\nindex = faiss.IndexFlatL2(dimension)  # Use L2 distance (Euclidean)\nindex.add(embeddings)  # Add combined embeddings to the index\nfaiss.write_index(index, \"faiss_index.index\")  # Save index to disk\nprint(\"FAISS index saved to 'faiss_index.index'.\")\n\n# Step 3: Function to process a query and compute its embedding\ndef compute_query_embedding(query):\n    \"\"\"\n    Computes the combined embedding for a query.\n    The query is expected to be a dictionary with specific keys corresponding\n    to the columns: 'Study Title', 'Primary Outcome Measures', etc.\n    \"\"\"\n    def compute_single_embedding(text):\n        \"\"\"\n        Computes the embedding for a single text input using the tokenizer and model.\n        \"\"\"\n        # Tokenize the text\n        encoded_input = tokenizer(\n            text, padding=True, truncation=True, max_length=128, return_tensors=\"pt\"\n        ).to(device)\n        \n        # Compute the embedding\n        with torch.no_grad():\n            model_output = model(**encoded_input)\n        \n        # Return the mean of the last hidden state\n        return model_output.last_hidden_state.mean(dim=1).squeeze().cpu().numpy()\n    \n    # Compute embeddings for each query component\n    query_embeddings = [\n        compute_single_embedding(query['Study Title']),\n        compute_single_embedding(query['Primary Outcome Measures']),\n        compute_single_embedding(query['Secondary Outcome Measures']),\n        compute_single_embedding(query['eligibility']),\n    ]\n    \n    # Combine all query embeddings into a single representation\n    return np.hstack(query_embeddings)\n\n# Example Usage\nexample_query = {\n    \"Study Title\": \"Exploring the effects of a new treatment on chronic pain\",\n    \"Primary Outcome Measures\": \"Reduction in pain scores after 12 weeks\",\n    \"Secondary Outcome Measures\": \"Improved mobility and quality of life\",\n    \"eligibility\": \"Participants aged 18-65 with chronic pain for at least 1 year\",\n}\n\nquery_embedding = compute_query_embedding(example_query).reshape(1, -1)\nprint(f\"Query embedding shape: {query_embedding.shape}\")","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T14:08:11.464475Z","iopub.execute_input":"2025-01-26T14:08:11.464828Z","iopub.status.idle":"2025-01-26T14:08:16.705641Z","shell.execute_reply.started":"2025-01-26T14:08:11.4648Z","shell.execute_reply":"2025-01-26T14:08:16.704691Z"}},"outputs":[{"name":"stdout","text":"Embedding columns: ['Study Title_embeddings', 'Primary Outcome Measures_embeddings', 'Secondary Outcome Measures_embeddings', 'eligibility_embeddings']\nCombined embeddings shape: (113101, 3072)\nFAISS index saved to 'faiss_index.index'.\nQuery embedding shape: (1, 3072)\n","output_type":"stream"}],"execution_count":17},{"cell_type":"code","source":"index = faiss.read_index(\"faiss_index.index\")\nprint(\"FAISS index loaded successfully.\")\n\n# Perform similarity search\nk = 10  # Number of nearest neighbors to retrieve\nD, I = index.search(np.expand_dims(query_embedding, axis=0), k)  # Search for k nearest neighbors\n\n# `D` contains distances, `I` contains indices of nearest neighbors\nprint(f\"Indices of nearest neighbors: {I}\")\nprint(f\"Distances to nearest neighbors: {D}\")\n\n# Retrieve the rows of the nearest neighbors\nnearest_neighbors = embedding_df.iloc[I[0]]\nprint(\"Nearest neighbors:\")\nprint(nearest_neighbors)","metadata":{"trusted":true,"execution":{"iopub.status.busy":"2025-01-26T14:08:16.706695Z","iopub.execute_input":"2025-01-26T14:08:16.706951Z","iopub.status.idle":"2025-01-26T14:08:18.408688Z","shell.execute_reply.started":"2025-01-26T14:08:16.706931Z","shell.execute_reply":"2025-01-26T14:08:18.407567Z"}},"outputs":[{"name":"stdout","text":"FAISS index loaded successfully.\n","output_type":"stream"},{"traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)","\u001b[0;32m<ipython-input-18-a5fc57f5021d>\u001b[0m in \u001b[0;36m<cell line: 6>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0;31m# Perform similarity search\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0mk\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;36m10\u001b[0m  \u001b[0;31m# Number of nearest neighbors to retrieve\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 6\u001b[0;31m \u001b[0mD\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mI\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mindex\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msearch\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mexpand_dims\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquery_embedding\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maxis\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mk\u001b[0m\u001b[0;34m)\u001b[0m  \u001b[0;31m# Search for k nearest neighbors\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      7\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      8\u001b[0m \u001b[0;31m# `D` contains distances, `I` contains indices of nearest neighbors\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;32m/usr/local/lib/python3.10/dist-packages/faiss/class_wrappers.py\u001b[0m in \u001b[0;36mreplacement_search\u001b[0;34m(self, x, k, params, D, I)\u001b[0m\n\u001b[1;32m    325\u001b[0m         \"\"\"\n\u001b[1;32m    326\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 327\u001b[0;31m         \u001b[0mn\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0md\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mshape\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    328\u001b[0m         \u001b[0mx\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mascontiguousarray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdtype\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m'float32'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    329\u001b[0m         \u001b[0;32massert\u001b[0m \u001b[0md\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0md\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;31mValueError\u001b[0m: too many values to unpack (expected 2)"],"ename":"ValueError","evalue":"too many values to unpack (expected 2)","output_type":"error"}],"execution_count":18},{"cell_type":"code","source":"# Step 5: Display results\nprint(f\"Query: {query_embedding}\")\nprint(\"\\nTop 10 Most Similar Entries:\")\nfor rank, idx in enumerate(I[0]):\n    if idx < len(df):  # Avoid out-of-bounds errors\n        print(f\"{rank + 1}.\")\n        print(f\"  NCT Number: {df.iloc[idx]['NCT Number']}\")\n        print(f\"  Study Title: {df.iloc[idx]['Study Title']}\")\n        print(f\"  Primary Outcome Measures: {df.iloc[idx]['Primary Outcome Measures']}\")\n        print(f\"  Secondary Outcome Measures: {df.iloc[idx]['Secondary Outcome Measures']}\")\n        print(f\"  eligibility: {df.iloc[idx]['eligibility']}\")\n        print(f\"  Distance: {D[0][rank]:.4f}\\n\")","metadata":{"trusted":true},"outputs":[],"execution_count":null},{"cell_type":"code","source":"import shap\nfrom sklearn.ensemble import RandomForestRegressor\n\n# Ensure `all_embeddings` and `D` are defined correctly\nall_embeddings = embeddings  # Use the combined embeddings created earlier\nD = D.flatten()  # Flatten the FAISS distances array\n\n# Ensure X_train and y_train sizes match\nX_train = all_embeddings[:len(D)]  # Feature matrix\ny_train = D  # Target variable (distances)\n\n# Define the original sources of the embeddings\nembedding_sources = [\"Study Title\", \"Primary Outcome Measures\", \"Secondary Outcome Measures\", \"eligibility\"]\n\n# Assume each source contributes an equal number of dimensions\ndimensions_per_source = X_train.shape[1] // len(embedding_sources)\n\n# Generate meaningful feature names\nfeature_names = [\n    f\"{source}_Dim{dim + 1}\"\n    for source in embedding_sources\n    for dim in range(dimensions_per_source)\n]\n\n# Debug: Ensure the number of feature names matches the number of dimensions\nassert len(feature_names) == X_train.shape[1], \"Mismatch in feature names and embedding dimensions!\"\n\n# Train the RandomForest model\nmodel = RandomForestRegressor()\nmodel.fit(X_train, y_train)\n\n# Use SHAP to explain the model\nexplainer = shap.Explainer(model, X_train)  # SHAP explainer\nshap_values = explainer(X_train[:10])  # SHAP values for the first 10 instances\n\n# Visualize SHAP values with meaningful feature names\nshap.summary_plot(shap_values, X_train, feature_names=feature_names)","metadata":{"trusted":true},"outputs":[],"execution_count":null},{"cell_type":"code","source":"import shap\nimport numpy as np\n\n# Assuming `shap_values` and `X_train` are already defined\n\n# Convert SHAP values and feature values to float64 for compatibility with JSON serialization\ninstance_index = 0  # Index of the instance to visualize\nshap_values_instance = shap_values[instance_index].values.astype(np.float64)  # Convert SHAP values to float64\nX_train_instance = X_train[instance_index].astype(np.float64)  # Convert feature values to float64\n\n# Initialize SHAP visualization in the notebook\nshap.initjs()\n\n# Visualize SHAP values for the first instance\nshap.force_plot(\n    explainer.expected_value,  # Expected value (the average model prediction)\n    shap_values_instance,  # The SHAP values for a given instance\n    X_train_instance,  # The actual feature values for that instance\n    feature_names=feature_names  # Provide feature names to make it interpretable\n)","metadata":{"trusted":true},"outputs":[],"execution_count":null}]}